John Martinez on April 28, 2026 8:55 pm Nice to see insider buying—usually a good signal in this space. Reply
Elijah G. Moore on April 28, 2026 8:55 pm Interesting update on Neuroscientist: “These Diseases Are Man Made” | Official Preview. Curious how the grades will trend next quarter. Reply
Jennifer Moore on April 28, 2026 8:57 pm I like the balance sheet here—less leverage than peers. Reply
Lucas Martinez on April 28, 2026 8:58 pm The cost guidance is better than expected. If they deliver, the stock could rerate. Reply
Elijah P. Johnson on April 28, 2026 8:58 pm I like the balance sheet here—less leverage than peers. Reply
Elizabeth R. Johnson on April 28, 2026 8:59 pm Interesting update on Neuroscientist: “These Diseases Are Man Made” | Official Preview. Curious how the grades will trend next quarter. Reply
Olivia Davis on April 28, 2026 9:00 pm Interesting update on Neuroscientist: “These Diseases Are Man Made” | Official Preview. Curious how the grades will trend next quarter. Reply
Oliver Brown on April 28, 2026 9:05 pm Production mix shifting toward Videos might help margins if metals stay firm. Reply
Isabella Brown on April 28, 2026 9:05 pm Uranium names keep pushing higher—supply still tight into 2026. Reply
Emma Taylor on April 28, 2026 9:06 pm Silver leverage is strong here; beta cuts both ways though. Reply
Jennifer Brown on April 28, 2026 9:07 pm Interesting update on Neuroscientist: “These Diseases Are Man Made” | Official Preview. Curious how the grades will trend next quarter. Reply
Emma Thomas on April 28, 2026 9:07 pm Production mix shifting toward Videos might help margins if metals stay firm. Reply
Elizabeth Jackson on April 28, 2026 9:07 pm Interesting update on Neuroscientist: “These Diseases Are Man Made” | Official Preview. Curious how the grades will trend next quarter. Reply
Elizabeth R. Hernandez on April 28, 2026 9:48 pm Good point. Watching costs and grades closely. Reply
Jennifer Miller on April 28, 2026 9:08 pm I like the balance sheet here—less leverage than peers. Reply
Elijah Martin on April 28, 2026 9:08 pm Silver leverage is strong here; beta cuts both ways though. Reply
Linda Rodriguez on April 28, 2026 9:09 pm Uranium names keep pushing higher—supply still tight into 2026. Reply
Olivia Johnson on April 28, 2026 9:09 pm I like the balance sheet here—less leverage than peers. Reply
Noah Hernandez on April 28, 2026 9:10 pm Interesting update on Neuroscientist: “These Diseases Are Man Made” | Official Preview. Curious how the grades will trend next quarter. Reply
38 Comments
Nice to see insider buying—usually a good signal in this space.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Interesting update on Neuroscientist: “These Diseases Are Man Made” | Official Preview. Curious how the grades will trend next quarter.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
I like the balance sheet here—less leverage than peers.
Good point. Watching costs and grades closely.
The cost guidance is better than expected. If they deliver, the stock could rerate.
I like the balance sheet here—less leverage than peers.
Interesting update on Neuroscientist: “These Diseases Are Man Made” | Official Preview. Curious how the grades will trend next quarter.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Interesting update on Neuroscientist: “These Diseases Are Man Made” | Official Preview. Curious how the grades will trend next quarter.
Good point. Watching costs and grades closely.
Production mix shifting toward Videos might help margins if metals stay firm.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Uranium names keep pushing higher—supply still tight into 2026.
Silver leverage is strong here; beta cuts both ways though.
Interesting update on Neuroscientist: “These Diseases Are Man Made” | Official Preview. Curious how the grades will trend next quarter.
Production mix shifting toward Videos might help margins if metals stay firm.
Good point. Watching costs and grades closely.
Interesting update on Neuroscientist: “These Diseases Are Man Made” | Official Preview. Curious how the grades will trend next quarter.
Good point. Watching costs and grades closely.
I like the balance sheet here—less leverage than peers.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Silver leverage is strong here; beta cuts both ways though.
Good point. Watching costs and grades closely.
Uranium names keep pushing higher—supply still tight into 2026.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
I like the balance sheet here—less leverage than peers.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Interesting update on Neuroscientist: “These Diseases Are Man Made” | Official Preview. Curious how the grades will trend next quarter.
Good point. Watching costs and grades closely.